MeSH tree: C04.588.894.797.520.109.220.249
The first computer algorithm capable of identifying which tumor cells are driving aggressive cancer growth has been developed by scientists from UCL and The Francis Crick Institute.
Dec 3, 2024
0
22
Already the go-to drug of choice for millions with type 2 diabetes, metformin might also fight lung cancer if those patients have it as well, new research shows.
Nov 27, 2024
0
40
In operable non-small cell lung cancer (NSCLC), molecular residual disease (MRD) detection via circulating tumor DNA (ctDNA) has emerged as a promising approach to identify individuals at high risk of disease recurrence and ...
Nov 7, 2024
0
14
Antibody-drug conjugates (ADCs) have emerged as a promising approach in cancer therapy, offering a 'magic bullet' strategy that combines the precision of monoclonal antibodies with the potency of cytotoxic drugs.
Oct 23, 2024
0
20
In new research, a team led by University of Cincinnati researchers has identified a potential new way to make radiation more effective and improve outcomes for patients with lung cancer that has spread to the brain. The ...
Oct 4, 2024
0
26
Houston Methodist researchers have developed an advanced mathematical model that predicts how novel treatment combinations could significantly extend progression-free survival for patients with non-small-cell lung cancer ...
Sep 27, 2024
0
51
The delivery of early, virtual palliative care has similar effects on quality of life as in-person care in patients with advanced non-small cell lung cancer (NSCLC), according to a study published online Sept. 11 in the Journal ...
Sep 17, 2024
0
34
Pfizer Inc.'s experimental drug for cancer weight loss was shown to help patients regain weight in a mid-stage study, offering fresh promise for treating the dangerous muscle-wasting condition.
Sep 16, 2024
0
53
While being overweight increases the risk of developing lifestyle-related diseases, there is a phenomenon known as the obesity paradox where a decreased risk of death has been seen during cancer therapy. However, that paradox ...
Sep 12, 2024
0
19
The tyrosine kinase inhibitor firmonertinib showed promising efficacy in patients with non-small cell lung cancer across a broad range of EGFR PACC mutations in the first-line metastatic setting with CNS antitumor activity, ...
Sep 9, 2024
0
21
